SynthesisCancer2026
Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta-analysis.
Synthesis in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors performed a systematic review and meta-analysis to estimate the prevalence of comorbidities among patients with myelodysplastic syndrome (MDS) by pooling results from 28 studies and 71,400 patients. In conducting this research, the authors observed that individuals with MDS have a high rate of cardiovascular disease that is 6.2 times greater than that in the general population. A remarkably high prevalence of heart failure (between 10.4% and 18.6%) was observed, indicating that heart failure is a major issue that warrants urgent attention in MDS. The prevalence of chronic kidney disease, chronic liver disease, and solid tumors was also higher in patients with MDS. The results of this analysis indicate a much higher prevalence of multimorbidity in patients who have MDS compared with the general population (79.1% vs. 63.4%; p < .0001). Furthermore, the data demonstrate that the association between MDS and noncommunicable diseases remains strong in both high-income and low-income regions, the comorbidity burden increases with higher scores on the revised International Prognostic Scoring System, patients with multimorbidity are twice as likely to die as those without multimorbidity, and a high burden of comorbidities emerges as a common problem in MDS, occurring in 35% of patients. These findings suggest that a focus on multimorbidity and a holistic, multidisciplinary, and patient-centered approach to address the challenge of common chronic diseases could significantly improve outcomes for patients with MDS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.